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1. Introduction
Urinary tract infections (UTIs) are one of the most 
common infectious pathologies worldwide (fol-
lowing lower respiratory tract infections and gas-
trointestinal infections) [1,2]. From the standpoint 
of public health, UTIs represent an important fac-
tor or morbidity and mortality, affecting both pa-
tients in primary care and tertiary care settings [3]. 
In fact, according to some estimates, around 50-
60% of women in the age range of 20–40 years ex-
perience a UTI at least once during their lifetime, 
while nosocomial UTIs may represent 25–50% of 
hospital-acquired infections overall [4]. The diag-
nosis and management of UTIs, and the corre-
sponding lost working days associated with these 
infections also have a significant economic conse-
quence, estimated to be around 3-5 billion US dol-
lars annually [5,6]. Uncomplicated UTIs are princi-
pally associated with members of the intestinal 
flora, with Escherichia coli representing 50-90% of 
these etiologies [7,8]; the spectrum of pathogens 
assicoated with nosocomial infections is more di-
verse, including non-fermenting Gram-negative 
bacteria, Gram-positive cocci (Staphylococcus au-
reus, S. saphrophyticus, Enterococcus spp.) and Can-
dida spp [9-11]. UTIs are associated with a variety 
of clinical signs and symptoms, including the 
burning sensation in the genitourinary region, 
strong and persistent urge to urinate, small vol-
ume of voided urine, urinary incontinence, pelvic 
pain, fever and nausea/vomiting [12]. Additionally, 
the color and consistency of the voided urine may 
be also subject to changes (cludy, red, bright pink, 
bloody, and foul-smelling urine) [12,13]. 
Urine samples (more commonly clean-catch/
midstream and catheter-specimen urine) are one 
of the most frequently submitted samples for cul-
ture to the clinical microbiology laboratories, ex-
ceeding the number of most of the other clinical 
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sample types [14]. Clean-catch urine samples are 
an inexpensive and non-invasive without the risk 
of complications; although contamination of the 
sample with the normal flora or the distal ureth-
rea is a risk, the appropriate instruction of patients 
regarding hygienic considerations and sample col-
lection is usually adequate for appropriate sam-
ples to be attained [15]. Nevertheless, collection of 
urine by using a single catherer is a more appro-
priate method to use to avoid contamination in 
hospitalized patients [1,2,15]. Bacteriological cul-
ture of urine samples on non-selective or chromo-
genic media (frequently coupled with the use of 
nitrite and leukocyte-esterase tests or a hemocy-
tometer) is the gold standard method in the etio-
logical diagnosis of UTIs. The interpretation of 
culture results (usually ≥105 colony forming units/
mL corresponding to singificant bacteriuria) from 
urine samples provide little or no challenge to 
clinical microbiologists [16]. Based on data from 
the literature, 50-70% of urine cultues are culture-
negative, while out of the positive urine samples, 
40-50% of isolated bacteria are relevant urinary 
pathogens [17]. Sample procurement, time elapsed 
before sample processing and expertise of the staff 
are all relevant factors in establishing the etiology 
of UTIs. However, some additional factors may 
influcence the results of succesful interpretation of 
urine cultues. It it well-known that microbiologi-
cal sampling should preferably be carried out be-
fore the administration of antibiotics, as these 
drugs may lead to false negative results (inhibit-
ing or significantly reducing bacterial growth), 
misleading clinicians and microbiologists [18]. To 
screen for this, routine microbiology laboratories 
often perform ancillary tests with pan-susceptible 
bacterial strains (e.g., Bacillus spp., E. coli) to assess 
the intrinsic antibacterial activity of the urine sam-
ples [19]. If these tests prove to be positive, clinical 
microbiologists may observe different rules dur-
ing interpretation of culture results.
Nevertheless, there is increasing evidence that 
various non-antibiotic pharmaceutical compounds 
may also have inhibitory properties on bacteria 
[20]; as a part of drug repurposing advances, sev-
eral drugs have also been screened for their anti-
microbial properties [21]. In addition, the pharma-
cokinetic properties of these drugs should also be 
taken into consideration, as many of these agents 
accumlate in/eliminated through urine, thus, they 
may possess the potency to adversely affect the 
growth of uropathogenic bacteria [22]. Therefore, 
the aim of our present study is to screen various 
non-antibiotic group pharmacological agents in 
vitro for their potential to augment the viability of 
pathogenic bacteria in urine samples or their 
growth on culture media during urinalysis. 
2. Materials and Methods
2.1. Chemicals
Sixty (n=60) pharmacological agents, encompass-
ing a wide variety of different chemical struc-
tures and mechanisms of action were tested dur-
ing our experiments: acetylsalicylic acid (Sigma-
Aldrich; Budapest, Hungary; will be listed as SA 
in the subsequent text), acetaminophen (SA), 
acetyl-cysteine (Teva Pharmaceuticals; Petah Tik-
va, Israel; will be listed as TPh in the subsequent 
text), acyclovir (TPh), allopurinole (SA), amanta-
dine (SA), ambroxol (TPh), atorvastatin (SA), atra-
curium (SA), azelastine (SA), bleomycin (TPh), 
cisplatin (TPh), celecoxib (Pfizer Hungary Ltd.; 
Budapest, Hungary), cetirizine (SA), chlorproma-
zine (SA), chloroxazone (SA), cidofovir (SA), 
clotrimazole (TPh), cyclophosphamide (Baxter; 
Deerfield, IL, United States), diclofenac (SA), dox-
orubicin (TPh), enalapril maleate (SA), etodolac 
(SA), famotidine (SA), fluconazole (SA), fluoxetine 
(SA), gemcitabine (TPh), guaifenesin (SA), indo-
methacin (Sanofi; Paris, France; will be listed as 
SP in the subsequent text), imipramine (SA), iver-
mectin (SA), metamizole-sodium (SF), mebenda-
zole (Richter Pharmaceuticals; Budapest, Hunga-
ry; will be listed as RPh in the subsequent text), 
lidocaine (SA), metoprolol succinate (SA), pacli-
taxel (TPh), prazozin (SA), metformin (SA), meth-
otrexate (Ebewe Pharma, Unterach am Attersee, 
Austria), prilocaine (SA), promethazine (SA), ris-
peridone (SA), simvastatin (SA), sitagliptine (SA), 
suxamethonium (SA), terbinafine (GlaxoSmith-
Kline Hungary Ltd., Budapest, Hungary), thiori-
dazine (SA), topotecan (SA), valsartan (SA), vera-
pamil (TPh), vincristine (TPh), xylomethazoline 
(SA), Vitamin B1 (EGIS Pharmaceuticals; Buda-
pest, Hungary; will be listed as EGIS in the sub-
sequent text), Vitamin B6 (EGIS), Vitamin B12 
(RPh), Vitamin C (SA), Vitamin D (EGIS), Vita-
min E (SA), Vitamin K (SA) and 5-fluorouracil 
(TPh). The compounds were chosen on a basis of 
being substrates of the organic cation transport-
er-2 (OCT2/SLC22A2), organic anion transporters 
1 and/or 3 (OAT1/SCL22A6 and OAT3/SCL22A8) 
and multi-antimicrobial extrusion protein 
(MATE), which are all relevant transporters in 
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the renal elimination of various pharmacological 
agents [23]. The list of relevant substrates was ac-
quired from the DrugBank database (https://
www.drugbank.ca/). 
Pharmaceutical compounds were dissolved in 
phosphate-buffered saline, with the exception of 
simvastatin and atorvastatin, which were dis-
solved in dimethyl sulfoxide (DMSO), in addition 
to Vitamin D and Vitamin K, which were dis-
solved in acetone and 70% ethanol, respectively. 
The final concentration of the tested compounds 
was set at 100 µg/mL in the experiments. 
2.2. Bacterial strains
The following bacterial strains were used during 
our growth inhibition experiments: Bacillus subtilis 
ATCC 6633, Escherichia coli ATCC 25922, Klebsiella 
pneumoniae ATCC 700603 (ESBL-producing) and 
Staphylococcus aureus ATCC 29213.
2.3. Culture media, paper disks
Bacterial strains were maintained on blood agar 
and eosine methylene blue plates (bioMérieux, 
Marcy-l’Étoile, France). Inhibitory activity of the 
tested compounds was investigated on Mueller-
Hinton agar plates (bioMérieux, Marcy-l’Étoile, 
France). 
Filter paper disks (7.0 mm in diameter, What-
man 3MM) were impregnated with the solutions 
of the tested compounds. Ciprofloxacin (5 µg), 
meropenem (10 µg) and trimethoprim/sulfameth-
oxazole (1.25/23.75 µg) disks (Liofilchem, Abruz-
zo, Italy) were used in the control experiments.
2.4. Inhibitory activity of non-antibiotic drugs
Detection of inhibitory activity among the tested 
compounds was performed on MHA plates, con-
taining B. subtilis ATCC 6633 spores [22,24,25]. A 
maximum of 6 sterile filter paper discs (impreg-
nated with 10 µL of the solutions of the solutions 
of different the tested compounds) were placed on 
MHA, containing a B. subtilis spore suspension 
(250 µl per 1 liters). Control strains (S. aureus, E. 
coli and K. pneumoniae) were plated on MHA agar 
conventionally, and the sterile filter paper discs 
were placed on the inoculated plates. The plates 
were incubated at 37 °C in an air thermostat. The 
inhibitory activity of the tested compounds was 
assessed semi-quantitatively; the zone of inhibi-
tion around the disks impregnated with the solu-
tions of the tested compounds were recorded after 
16–18 h of incubation, using a caliper (expressed as 
milimeters ± standard deviation [SD]). Any meas-
ureable zone of inhibition was considered as posi-
tive [22,24,25]. DMSO (at 2 V/V% concentration) 
was used as a negative control for the tested com-
pounds, while ciprofloxacin, meropenem and tri-
methoprim/sulfamethoxazole disks were used as 
positive controls. All experiments were performed 
in triplicate.
3. Results
Out of the 60 tested pharmacological agents, nine-
teen (n=19) compounds presented with various 
levels of inhibitory activity on the tested bacterial 
strains. The results of our disk diffusion inhibitory 
experiments are presented in Table I. Out of the 
nineteen compounds, four compounds (atracuri-
um, doxorubicin, lidocaine, thioridazine) showed 
measurable inhibition zones on K. pneumoniae 
ATCC 700603 (ranging between 2-6 mm), while 
seven compounds (atracurium, celecoxib, chlor-
promazine, doxorubicin, imipramine, lidocaine, 
thioridazine) showed inhibitory activity on E. coli 
ATCC 25922 (with zone diameters ranging be-
tween 1-7 mm). S. aureus ATCC 29213 was more 
susceptible to the inhibitory activity of the tested 
drugs (zone diameters ranging between 4-14 mm; 
for 16 out of the 19 compounds), with the excep-
tion of allopurinole, methotrexate and verapamil). 
The compounds showed the highest levels of in-
hibitory activity on B. subtilis ATCC 6633, which is 
one of the main bacterial strains used for the 
screening of the ’intrinsic’ antibacterial activity of 
urine; with zone diameters ranging between 4 mm 
(allopurinole) and 22 mm (thioridazine). All tested 
reference antibiotics showed zone diameters for 
the respective bacterial strains, which correspond-
ed to the ’susceptible’ therapeutic category (based 
on EUCAST v. 9.0 breakpoints). 2 V/V% DMSO did 
not show any inhibitory activity during the exper-
iments. 
4. Discussion
UTIs are a major publich health and economic 
burden to healthcare infrastructres worldwide, 
therefore the correct determination of the etiologi-
cal agents in these infections in of utmost impor-
tance [1-3, 5, 11, 25, 26]. During urinalysis, all pos-
sible confounding variables must be taken into 
consideration, which may distort the culture re-
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sults of routine laboratories. These may include is-
sues during sample procurement and time 
elapsed before sample has been processed (i.e. the 
pre-analytical phase), however, troubleshooting 
must also encompass steps in the analytical phase 
[27]. The chemical composition of urine clearly af-
fects the viability and species-composition of bac-
teria, for example, if the pH of the urine shifts in 
either directions, it may inhibit or potentiate the 
replication of several microorganisms [26,27]. 
Many natural compounds and constituents of our 
diet have well-known antibacterial properies (e.g., 
ajoene [28], betulinic acid [29], cranberry juice [30], 
curcumin [31], essential oils [32], horse raddish 
[33], pepper [34], resveratrol [35] and zeaxantin 
[36]), which may influence bacterial viability in 
urine. Nevertheless, the relevance of non-antibiot-
ic compounds in this regard must not be underes-
timated [20,21,37]; this is especially true in case of 
older patients, whom many drugs are simulate-
nously prescribed [38]. In our study, nineteen out 
of the sixty tested pharmacological agents pre-
sented with growth inhibitory properties on the 
tested bacterial strains. With the inclusion of S. 
aureus, E. coli and K. pneumoniae in the study, we 
aimed to assess the relevance of these drugs in 
decreasing the viability of pathogenic bacteria in 
urine; in contrast, the B. subtilis strain is predomi-
nantly used to provide information on the anti-
bacterial activity of the urine sample itself. While 
4-16 compounds (depending on the bacterial 
strain) showed growth inhibitory activity on the 
reference strain, n=19 drugs inhibited the growth 
of B. subtilis in the disk diffusion tests to various 
extents. This experiental result may point out that 
in addition to antibiotics, non-pharmacological 
agents may also be responsible to „positive” tests, 
when assessing the antibacterial activity of the 
urine samples received, depending on the con-
centration, in which they are available in the 
Table I Inhibitory activity of tested pharmaceutical compounds (results expressed as mm ± SD)









Allopurinole 4 ± 1 Ø Ø Ø
Atorvastatin 11± 2 Ø Ø 8 ± 2
Atracurium 14 ± 2 5 ± 1 3 ± 1 6 ± 1
Bleomycin 16 ± 2 Ø Ø 8 ± 3
Celecoxib 20 ± 3 1 ± 1 Ø 14 ± 2
Chlorpromazine 17 ± 3 3 ± 1 Ø 10 ± 2
Clotrimazole 15 ± 2 Ø Ø 5 ± 2
Doxorubicin 18 ± 3 5 ± 2 5 ± 1 8 ± 2
Etodolac 15 ± 3 Ø Ø 7 ± 1
Fluconazole 17 ± 1 Ø Ø 7 ± 2
Imipramine 9 ± 2 3 ± 3 Ø 4 ± 2
Ivermectin 14 ± 3 Ø Ø 8 ± 3
Lidocaine 17 ± 4 7 ± 2 6 ± 1 10 ± 3
Mebendazole 16 ± 1 Ø Ø 12 ± 2
Methotrexate 10 ± 2 Ø Ø Ø
Promethazine 7 ± 2 Ø Ø 6 ± 3
Simvastatin 13 ± 2 Ø Ø 10 ± 2
Thioridazine 22 ± 4 5 ± 1 2 ± 1 9 ± 3
Verapamil 6 ± 3 Ø Ø Ø
 
Ciprofloxacin (5 µg) 24 ± 3 27 ± 3 26 ± 2 26 ± 2
Meropenem (10 µg) 29 ± 2 24 ± 1 23 ± 1 24 ± 1
Trimethoprim/sulfamethoxazole 
(1.25/23.75 µg) 
16 ± 3 19 ± 1 18 ± 2 16 ± 2
Ø: no inhibition zones were observed
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urine [22]. Similarly to our results, the potential 
antibacterial activity of azole antifungal agents 
[39], antracyclines [40], phenothiazines [41], local 
and general anesthetics [42], peripherially acting 
muscle relaxants [43], non-steroidal anti-inflam-
matory drugs [44] and statins [45] were already 
demonstrated by studies in different settings. 
However, other studies also highlighted the anti-
bacterial properties of acetyl-salicylic acid [46], al-
lopurinole [47], various cardio-vascular medica-
tions [48], and several vitamins (A, C, D and K) 
[49-52]; this was not demonstrated in our in vitro 
settings.
5. Conclusions
In conclusion, the aim of our present study was 
produce in vitro data on the possible role of non-
antibiotic pharmacological agents, as inhibitors of 
growth during urinalysis, i.e. the culture of urine 
samples on bacteriological media, if a UTI is sus-
pected. Our results show that a wide variety of 
structurally unrelated drugs may have the poten-
tial to inhibit the growth of urinary pathogens, or 
B. subtilis, a commonly used microorganism in an-
cillary tests. Although the methodology used dur-
ing our experients (disk diffusion) offers only pre-
liminary, semi-quantitative results and the experi-
ments were carried out in a select group of bacte-
ria, our results suggest that further experiments, 
involving additional pharmacological agents is 
warranted, to establish the full extent of their in-
fluence on the appropriate culture of urine sam-
ples. 
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